Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line

Berlin, Germany, July 13, 2021:

ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System DirectedLuckTM as well as for their proprietary suspension HEK293 cell line.

DirectedLuck has been optimized to recognize specific epigenetic marks. It guides the transgene to regions with highest transcriptional activity. This ensures extraordinary high protein expression and maximal stability. The DirectedLuck Transposase is compatible with additional genetic elements in standard expression vector design and can be used with any host cell line. ProBioGen's HEK293 has been optimized for manufacture of proteins and viral vectors and is distinguished by robust growths in chemically defined medium in suspension culture, making it a valuable tool for production in large bioreactors.

Dr. Volker Sandig, Chief Scientific Officer at ProBioGen commented: "We are delighted to sign this Research Agreement with Heat Biologics for two of our technologies. This confirms the value of our patent portfolio, which we have been continuously expanding for years. It is great to see the application of these technologies beyond protein and virus production now also in allogeneic cell therapy."

About ProBioGen

ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.

The combination of ProBioGen's CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen has been operational for more than 27 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.

 

ProBioGen Contact:

Dr. Gabriele Schneider
Chief Business Officer
cmo@probiogen.de
+49 (0)30 3229 35 100
www.probiogen.de

ProBioGen Press Contact:

Sarah Wandrey
Corporate Communications
press@probiogen.de

Go back